RecruitingPhase 1NCT07342114

A Dose-Escalation Study of RO7875913 in Healthy Participants

A Phase I Dose-Escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of RO7875913 in Healthy Volunteers

Sponsor

Genentech, Inc.

Enrollment

40 participants

Start Date

Mar 11, 2026

Study Type

INTERVENTIONAL

Conditions

The purpose of this study is to evaluate the safety, pharmacokinetics, and pharmacodynamics of RO7875913 in healthy participants.

Min Age: 18 YearsMax Age: 65 Years

Agreement to adhere to the contraception requirements
Body weight > 40 kilogram (kg) with a body mass index of 18-30 kg per meter square (kg/m\^2)

Positive test result for hepatitis B surface antigen, hepatitis C virus (HCV), or human immunodeficiency virus (HIV) antibody screen
History of any malignancy
Major surgical procedure within 28 days prior to initiation of study treatment, or anticipation of need for a major surgical procedure during the study
History or clinical manifestations of significant metabolic, hepatic, renal, pulmonary, cardiovascular, hematologic, gastrointestinal, urologic, neurologic, or psychiatric disorders
Known allergy or hypersensitivity to any component of the RO7875913 formulation
Treatment with investigational biologic therapy (or blinded comparator) within 90 days or 5 drug elimination half-lives, whichever is longer, prior to initiation of study drug
Treatment with investigational non-biologic therapy (or blinded comparator) within 28 days or 5 drug elimination half-lives, whichever is longer, prior to initiation of study drug
Treatment with any immunosuppressive medication within 28 days or 5 drug elimination half-lives, whichever is longer, prior to initiation of study drug